In the context of prior treatment failure, absence of other actionable mutations, and the plausible functional impact of this non-canonical structural variant, a clinical decision was made to initiate trial use of pralsetinib (400 mg orally once daily), which had previously demonstrated efficacy and good tolerability in RET fusion-positive NSCLC (7, 10). The gene discussed is RET; the disease is non-small cell lung carcinoma.